key: cord-0761578-h8ltsjqt
authors: Santosa, A.; Xu, C.; Arkachaisri, T.; Kong, K. O.; Lateef, A.; Lee, T. H.; Leong, K. H.; Low, A. H.; Sriranganathan, M. K.; Tan, T. C.; Teng, G. G.; Thong, B. Y.; Fong, W.; Lahiri, M.
title: Recommendations for COVID-19 Vaccination in People with Rheumatic Disease: Developed by the Singapore Chapter of Rheumatologists
date: 2021-03-08
journal: nan
DOI: 10.1101/2021.03.01.21252653
sha: 34b728a3e276b6a2ca11e9721ba9ef460a377bb6
doc_id: 761578
cord_uid: h8ltsjqt

Aim People with rheumatic diseases (PRD) remain vulnerable in the era of the COVID-19 pandemic. We formulated recommendations to meet the urgent need for a consensus for vaccination against SARS-CoV-2 in PRD. Methods Systematic literature reviews were performed to evaluate (1) outcomes in PRD with COVID-19; (2) efficacy, immunogenicity and safety of COVID-19 vaccination; and (3) published guidelines/recommendations for non-live, non-COVID-19 vaccinations in PRD. Recommendations were formulated based on the evidence and expert opinion according to the Grading of Recommendations Assessment, Development and Evaluation methodology. Results The consensus comprises two overarching principles and seven recommendations. Vaccination against SARS-CoV-2 in PRD should be aligned with prevailing national policy and should be individualized through shared decision between the healthcare provider and patient. We strongly recommended that eligible PRD and household contacts be vaccinated against SARS-CoV-2. We conditionally recommended that the COVID-19 vaccine be administered during quiescent disease if possible. Immunomodulatory drugs, other than rituximab, can be continued alongside vaccination. We conditionally recommended that the COVID-19 vaccine be administered prior to commencing rituximab if possible. For patients on rituximab, the vaccine should be administered a minimum of 6 months after the last dose and/or 4 weeks prior to the next dose of rituximab. Post-vaccination antibody titres against SARS-CoV-2 need not be measured. Any of the approved COVID-19 vaccines may be used, with no particular preference. Conclusion These recommendations provide guidance for COVID-19 vaccination in PRD. Most recommendations in this consensus are conditional, reflecting a lack of evidence or low-level evidence.

one paediatric rheumatologist and one infectious diseases specialist. A conflict-of-interest declaration was required from all members of the CWG and TFP prior to the consensus process.

All members declared no conflict of interest.

The CWG sent out preselected topics to the TFP and sought their input on additional clinically important topics. Considering the TFP's input, the CWG selected the following core topics relevant to clinical decision-making for COVID-19 vaccination:

A recent systematic review and meta-analysis of global data showed that PRD remain vulnerable, with substantial rates of severe outcomes (3). The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 58% (95% confidence interval (CI) 48% -67%), 33% (95% CI 21% -47%), 9% (95% CI 5% -15%) and 7% (95% CI 3% -11%), respectively, which are comparable with data from the COVID-19 Global Rheumatology Alliance (GRA) physician registry. The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) of general population infected with COVID-19 in the WHO database, although age, gender and comorbidities were not matched (3). D'Silva et al reported a higher risk of hospitalization, ICU admission, mechanical ventilation, acute kidney injury, renal replacement therapy and death based on TriNetX, a multi-center research network with real-time electronic health record data across 35 healthcare organizations in the US (16) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The authors concluded that these outcomes were likely mediated by a higher comorbidities burden in PRD, such as hypertension, diabetes mellitus, chronic kidney disease and asthma.

Two mRNA vaccines are currently approved by the US FDA and Singapore HSA. It is known that selected DNA and RNA molecules have the unique property to activate the immune system, through activation of Toll-like receptors. It has been shown that the innate immune response would be suppressed by nucleoside modification of RNA, as the innate immune system detects RNA lacking nucleoside modification as a means of selectively responding to bacteria or viruses (17, 18) . Both mRNA COVID-19 vaccines from Pfizer/BioNTech ® and Moderna ® are nucleoside-modified RNA. Thus, the risk of autoimmune disease flare after receiving mRNA COVID-19 vaccine may more likely result from the adaptive immune response to spike protein synthesized by mRNA, rather than the innate immune response to nucleoside-modified RNA. Theoretically, this is no different from the risk from other protein / conjugate vaccines, which have been in use for many years and have been confirmed to be safe in PRD.

There were 62 (0.3%) participants who had rheumatic disease and received BNT162b2 mRNA COVID-19 vaccine in the Pfizer/BioNTech ® trial (4) . No flare of autoimmune disease was reported. Certainly, larger sample size and long-term follow-up studies are needed to further ascertain the risk of flares in autoimmune diseases.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (9) and the Sputnik V ® Russian vaccine by Gamaleya (8) and protein subunit vaccines (such as the Novavax ® vaccine (11)) similarly provide little data in PRD. Pertinent information from primary COVID-19 vaccine trials to date are summarized in Table 1 (4, 5, 8, 9, 19) .

There are currently no available data on the immunogenicity and efficacy of COVID-19 vaccination in PRD.

To review the evidence in non-live, non-COVID-19 vaccinations in PRD, a systematic review of international best practice guidelines and recommendations from rheumatology societies on vaccinations in PRD was performed, in lieu of a systematic review of the primary literature. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021 . ;

OR (immunocompromised patient[MeSH Terms]). The filters English (language) and Humans were applied. This search yielded 191 citations. One member of the CWG (ML) screened through the titles and/or abstracts and excluded those that were not a practice guideline, not targeted to PRD, only addressed live vaccines, were only targeted to childhood vaccines, did not undertake a systematic literature review, were duplicates, or were outdated recommendations from the same body. Four additional citations were added from manual search. We then reviewed the remaining 21 full text articles and excluded best practice guidelines that did not undertake a consensus methodology and evidence grading or strength of recommendations. Eleven full text articles were finally included ( Figure 1 , Table 2 ) (20-32).

The definitions of PRD and immunomodulatory drugs considered in this recommendation are summarized in Table 3 Creation of preliminary statements and rating

The CWG met to formulate and finalize preliminary statements for rating by the TFP, which was conducted on an online survey platform. The TFP were provided with summarized evidence from the reviewed trials and guidelines, a link to an online rating form and rating instructions. Based on their expertise and the provided literature, each TFP member independently rated each statement on a five-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree); an agreement was defined as a score of 4 or 5. A consensus was obtained if there was ≥70% agreement. The CWG and the TFP convened via a teleconferencing platform, where the aggregated findings were presented and discussed.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Definitions were clarified and statements were reworded, if needed. As there was consensus on all statements following the online voting round, no further round of voting was conducted.

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (32) was used to determine the strength of recommendations. In determining the strength of recommendations, the TFP considered the level of evidence available, as well as the balance between the potentially expected benefits and risks from COVID-19 vaccination/ omission of vaccination in PRD. Recommendations were categorized as "strong" when benefits/risks clearly outweighed the other, and "conditional" when benefits/risks were closely balanced or uncertain.

The final consensus statement was circulated to the TFP after the consensus meeting and was approved by all members.

The final consensus statements consist of two overarching principles and seven recommendations. They are summarized in Table 4 .

1. Vaccination in PRD should be aligned with prevailing national policy.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The knowledge on COVID-19 vaccination is rapidly evolving with various candidate vaccines still undergoing clinical trials. As new evidence becomes available, the landscape of vaccine availability in each country will likely differ. It is important that healthcare professionals align their recommendations to prevailing national policy, to ensure consistency of messages to patients and maintain streamlined safety workflows. Vaccine safety monitoring systems, such as the vaccine adverse event reporting system (VAERS) are in place to detect possible safety signals in the vaccinated population. Locally, the HSA reviews all reports of post-vaccination reactions, to inform national policy of vaccine eligibility, monitoring and precautions. 

This recommendation is extrapolated from other vaccine recommendations in PRD, and is largely based on expert opinion, hence the conditional strength of recommendation.

Vaccination studies in PRD have been largely conducted during quiescent disease state (20, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The decision for vaccination in patients whose disease is not quiescent should be considered on an individual patient level.

Vaccination studies in PRD on immunomodulatory drugs (other than B cell depleting therapy) have shown sufficient protective efficacy with common non-live vaccines including influenza and pneumococcal vaccines, despite somewhat reduced immunogenicity particularly with methotrexate and abatacept (21, 24, 27) . B cell depleting therapy with rituximab is associated with significant reduction in immunogenicity. Despite reduced humoral immune response, cellular immune response is still preserved after influenza vaccination in patients who were treated with rituximab (38) .

Satisfactory immunogenicity has been shown in rituximab treated patients when influenza and pneumococcal vaccines were administered 6 months after a previous dose (20, 28, 39) and at least 4 weeks prior to a subsequent dose (22, 23) , forming the basis of this conditional recommendation. Of note, the British Arthritis and Musculoskeletal Alliance recommends that . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Outside of paediatric care (30) , post-vaccination antibody titre measurement is not part of routine clinical practice and is not part of other vaccination guidelines in adult PRD. As the correlation between antibody titres post COVID-19 vaccination and clinical protection is not well established at present, we conditionally recommend that titres not be measured.

Vaccination of household contacts has been advocated by societies such as European Alliance of Associations for Rheumatology (EULAR) (20) and Infectious Diseases Society of America (IDSA) (28) for a variety of inactivated and live vaccines (except for the oral polio vaccination (20, 21, 28) ). Increasingly, epidemiologic studies have demonstrated SARS-CoV-2 transmission in close contacts due to asymptomatic and pre-symptomatic infections (40) (41) (42) , highlighting the importance of extending vaccinations to household contacts in order to protect vulnerable patients.

with no particular preference.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.01.21252653 doi: medRxiv preprint

The various SARS-CoV-2 vaccines in development are non-live vaccines. The anticipated risk benefit ratio should therefore be similar for vaccinations to be recommended without preference for any particular vaccine. However, long term follow-up in PRD will be needed to ascertain longer term efficacy and safety of the various vaccines.

The consensus recommendations for COVID-19 vaccination in PRD presented in this article were based on review of the limited currently available literature with these vaccines, supplemented by the more extensive knowledge that is available for other non-live vaccines in PRD. It is noteworthy that the absence of evidence is not evidence of absence, and practical recommendations for PRD need to be made despite the scarcity of literature in these vulnerable patients. Experts in the specialty were consulted, in order to synthesize the available literature into clinically meaningful recommendations. Available evidence on the risk of COVID-19 in PRD was weighed against the potential risks / benefits of vaccination with a new vaccine technology, borrowing from the principles of vaccination with non-live viruses in PRD and the available knowledge on mRNA drug delivery systems.

In formulating these recommendations, the TFP were cognizant of the heightened risk of COVID-19 in our patients. Therefore, recommendations were formulated to aid practicing rheumatologists in their decision making without being overly restrictive, while allowing individualized decision making for each patient. These should take into account patient's disease status, ongoing treatment, risk profiles, preferences and local community transmission risk.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Articles for full text review = 17

Excluded after title and abstract review = 174 (not a practice guideline / not targeted to patients with rheumatic disease / only addresses live vaccines / only targeted to childhood vaccines / did not undertake a SLR / duplicate / updated guidance from same body)

Excluded after full text review = 10

Added by manual search = 4

Articles included = 11

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.01.21252653 doi: medRxiv preprint

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Annals of the rheumatic diseases

Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi-Center Comparative Cohort Study. Arthritis & rheumatology

Clinical Outcomes of COVID-19 in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis of Global Data

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine

HSA Grants Interim Authorisation for Moderna COVID-19 Vaccine in Singapore

Reccommendations on Singapore's COVID-19 Vaccination Strategy by the Expert Committee on COVID-19 Vaccination 2021

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial. 11. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy i UK Phase 3 Trial

Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

Policy and Procedure Manual for Clinical Practice Guidelines

On the Coronavirus (COVID-19) Outbreak and the Smart City Network: Universal Data Sharing Standards Coupled with Artificial Intelligence (AI) to Benefit Urban Health Monitoring and Management

Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the rheumatic diseases

The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease

Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases

Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases

Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Conjugate Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Immune Thrombocytopenia in a 22-Year-Old Post Covid-19 Vaccine. American journal of hematology. 2021. 34. Principles for COVID-19 Vaccination in Musculoskeletal and Rheumatology for Clinicians 2021

Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. 36. Prevention CfDCa. Interim Clinical Considerations for Use of mRNA

Vaccines Currently Authorized in the United States

High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus

The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab

American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China

Clinical study protocol of a phase 3, randomised, observer-blinded, placebocontrolled trial to evaluate the efficacy and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with matrix-M1 TM adjuvant in adult participants 18-84 years of age in the United Kingdom

Biologic DMARDs (anti-tumour necrosis factor, tocilizumab, rituximab, abatacept, secukinumab, ixekizumab, anakinra, belimumab)

Targeted synthetic DMARDs (tofacitinib, baricitinib, upadacitinib*)

Immunosuppressive drugs (cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporin A, tacrolimus)

Furer V, et al. (20) Non-live PRD on IS/ DMARD/ GC